BioClinica Signs Enterprise Agreement for Electronic Data Capture
BioClinica today announced that it has signed a three-year, multi-million dollar agreement for enterprise-wide EDC technology and data management services with a global, multibillion dollar division of a Top 10 pharmaceutical company. Designed for maximum efficiency and flexibility, BioClinica Express will support nearly 200 studies annually for this organization. Together the firms have developed a common data model based on CDISC standards that will facilitate rapid deployment and study closeout while supporting a challenging clinical environment.
The client chose BioClinica Express as part of a broad evaluation of all the leading solutions to achieve its goal of running paperless clinic studies. This agreement marks the second enterprise-level, fullservice EDC agreement that BioClinica has announced this year. BioClinica announced a similar agreement for BioClinica Express and data management services with Cephalon in February.
BioClinica Express is a comprehensive EDC solution that coordinates and organizes the collection and dissemination of clean data, adding speed and quality to the clinical trial process. Express will be used for direct data entry and BioClinica’s full service data management staff will assure that all data is cleaned and processed in a timely manner.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
